Profile data is unavailable for this security.
About the company
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
- Revenue in USD (TTM)66.98m
- Net income in USD-71.54m
- Incorporated1995
- Employees120.00
- LocationEnanta Pharmaceuticals Inc4 Kingsbury AvenueWATERTOWN 02472United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.enanta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AC Immune SA | 5.61m | -92.28m | 289.18m | 133.00 | -- | 3.61 | -- | 51.52 | -0.9183 | -0.9183 | 0.0559 | 0.7984 | 0.021 | -- | 0.3392 | 42,203.34 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 297.28m | 143.00 | -- | 1.39 | -- | 8.75 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 298.62m | 18.00 | -- | 46.84 | -- | 20.41 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Puma Biotechnology Inc | 228.37m | 31.11m | 326.63m | 179.00 | 10.52 | 2.48 | 7.77 | 1.43 | 0.6104 | 0.6104 | 4.51 | 2.59 | 1.06 | 8.17 | 5.33 | 1,275,816.00 | 14.48 | 4.80 | 24.66 | 8.38 | 74.53 | 74.14 | 13.62 | 4.58 | 1.93 | 14.66 | 0.1473 | 0.00 | -0.9099 | 0.2881 | 2.75 | -- | -67.65 | -- |
| Akebia Therapeutics Inc | 236.20m | -5.35m | 337.53m | 194.00 | -- | 10.26 | -- | 1.43 | -0.0179 | -0.0179 | 0.8976 | 0.1229 | 0.791 | 2.55 | 5.80 | 1,217,505.00 | -1.79 | -27.07 | -3.03 | -45.24 | 82.83 | 78.83 | -2.26 | -45.92 | 1.46 | 1.07 | 0.8558 | -- | 47.46 | -4.33 | 92.30 | -- | 91.19 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 421.07m | 120.00 | -- | 3.33 | -- | 6.29 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| Elite Pharmaceuticals Inc | 140.12m | 43.41m | 421.32m | 68.00 | 10.11 | 5.23 | 9.36 | 3.01 | 0.0387 | 0.0387 | 0.1268 | 0.0748 | 1.29 | 3.03 | 4.18 | 2,060,564.00 | 39.98 | 13.18 | 45.86 | 16.01 | 51.06 | 47.19 | 30.98 | 13.97 | 5.44 | -- | 0.0517 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 465.42m | 900.00 | 6.95 | 0.8133 | 2.67 | 0.590 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 469.05m | 46.00 | 6.33 | 2.31 | 6.25 | 2.72 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Invivyd Inc | 50.04m | -59.86m | 485.02m | 99.00 | -- | 3.96 | -- | 9.69 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 486.74m | 31.00 | -- | 21.05 | -- | 6.92 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 511.74m | 59.00 | 15.38 | 3.84 | 12.58 | 6.06 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 513.63m | 142.00 | -- | -- | -- | 11.84 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
Data as of Mar 03 2026. Currency figures normalised to Enanta Pharmaceuticals Inc's reporting currency: US Dollar USD
63.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 3.73m | 12.92% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 2.77m | 9.61% |
| Krensavage Asset Management LLCas of 31 Dec 2025 | 2.77m | 9.59% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.12m | 7.34% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.08m | 7.22% |
| Deep Track Capital LPas of 31 Dec 2025 | 1.96m | 6.78% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 885.13k | 3.07% |
| BlackRock Advisors LLCas of 31 Dec 2025 | 764.01k | 2.65% |
| Millennium Management LLCas of 31 Dec 2025 | 670.43k | 2.32% |
| Geode Capital Management LLCas of 31 Dec 2025 | 645.79k | 2.24% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
